Skip Navigation LinksHome > March 1982 - Volume 59 - Issue 3 > Bromocriptine and Norethisterone in the Treatment of Premens...
Obstetrics & Gynecology:
Original Article: PDF Only

Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome.

YLÖSTALO, PEKKA MD; KAUPPILA, ANTTI MD; RÖNNBERG, LARS MD; JÄNNE, OLLI MD

Collapse Box

Abstract

Thirty-six women suffering from premenstrual syndrome were treated with bromocriptine or norethisterone in a randomized placebo-controlled double-blind study. Bromocriptine decreased breast engorgement and irritability (P<.01) and also decreased the total score of all symptoms (P<.05). Weight gain during the luteal phase was smaller (P<.05) during bromocriptine than during placebo treatment. Norethisterone treatment alleviated (P<.05) breast tenderness. Changes in hormonal parameters and liver function tests during bromocriptine treatment were minimal, whereas norethisterone decreased serum levels of luteinizing hormone (P<.01), follicle-stimulating hormone (P<.001), and progesterone (P<.05), while increasing the serum level of prolactin (P<01) and [gamma] -glutamyltranspeptidase activity (P<.05). Serum levels of cholic acid and chenodeoxycholic acid remained unchanged during both therapies. Bromocriptine treatment brought about side effects in 6 and norethisterone in 3 women. At the doses used, bromocriptine appears more efficient than norethisterone with regard to premenstrual symptoms, although norethisterone is better tolerated.

(C) 1982 The American College of Obstetricians and Gynecologists

Login

Article Tools

Share